Pulsetto FIT X
Cervical · bilateral · hands-free
$399 observedEditorial independence: Neuro Device Lab may earn affiliate commissions from some links. Commercial relationships do not change the inclusion, evidence-scoring or negative-study rules used in this report.
Executive summary
The consumer VNS market has moved beyond a single device format. In 2026, consumers can choose between cervical neck stimulators and auricular ear-based systems, with meaningful differences in price, session design, evidence maturity, recurring costs and regulatory positioning.
NDL's audit identified 11 direct-electrical consumer models in its current model-level census. Because several brands sell multiple SKUs, the report also uses a seven-platform denominator to avoid allowing multi-model product lines to distort evidence coverage.
“More studies” is not the same as “stronger evidence.” NDL treats device specificity, randomization, sham quality, sample size, conflicts and primary outcomes as separate questions.
Citation-ready finding: In NDL's conservative platform-level audit, 4 of 7 consumer VNS platforms (57.1%) had independently verified peer-reviewed human research tied to the exact device or platform, while 3 of 7 (42.9%) had credible sham-controlled evidence located in the audit. These figures are dataset-specific, not estimates of the entire global neuromodulation industry.
NDL proprietary snapshot
2026 Market at a Glance
Four signals summarize the current consumer VNS market: a roughly even split between neck and ear stimulation, a mid-$300s observed device price, uneven device-specific evidence, and rapidly rising branded search interest around Pulsetto.
Audited models11direct-electrical consumer models
Median observed price$354USD-priced audited models
Peer-reviewed evidence4 / 7consumer platforms independently verified
Pulsetto search interest+170%12-month YoY relative-interest signal in supplied Trends capture
For publishers: Charts may be referenced with attribution to “Neuro Device Lab, Consumer Vagus Nerve Stimulation Market Report 2026.” Statistics should retain the stated denominator and September 21, 2026 cutoff.
1. What counts as a consumer VNS device?
The core denominator includes products that are non-invasive, electrically stimulate an anatomical vagus-nerve target, and are accessible to consumers or patients in 2026. NDL separates direct electrical VNS from non-electrical products marketed around vagal modulation and from adjacent nervous-system wearables.
| Class | Definition | Examples | Core denominator? |
|---|---|---|---|
| A | Direct electrical non-invasive VNS | Pulsetto, Nurosym/NuroPod, Truvaga, Xen, Vagustim, ZenoWell, VeRelief | Yes |
| B | Vagus-targeting but non-electrical | Sensate | No — reported separately |
| C | Adjacent nervous-system devices | Apollo Neuro and similar products | No |
| Clinical benchmark | Regulated clinical VNS used as an evidence/regulatory comparator | gammaCore Sapphire | No |
A recent peer-reviewed review independently describes an OTC VNS market including Nurosym/NuroPod, Xen, ZenoWell, tVNS products, Truvaga, Pulsetto and VeRelief, while distinguishing Sensate's infrasonic approach.
2. 2026 consumer VNS product landscape
Product visuals are locally hosted WebP assets where NDL already has verified product imagery. Where a permission-cleared product image is not yet in the NDL asset library, the card links directly to the official manufacturer source rather than presenting a webpage screenshot as product photography. Because product pages and promotions change, the report records access dates rather than treating any current page as permanent evidence.
Pulsetto FIT
Cervical · bilateral · hands-free
$269–$296 observed
Pulsetto Lite
Cervical · bilateral · hands-free
$224–$269 observedOfficial product sourceView manufacturer page
Nurosym
Auricular · ear electrode
€700 current official listingTruvaga Plus
Cervical · handheld
$499Truvaga 350
Cervical · handheld · 350 sessions
$325Official product sourceView manufacturer page
ZenoWell Luna
Auricular · left ear
$409 current official listingOfficial product sourceView manufacturer page
ZenoWell Vita Mini
Auricular · left ear
$2393. Pricing: a market spanning entry-level to premium neurotechnology
Among the audited models with USD price observations, the median observed device price was $354. The range in the current dataset ran from $224 for Pulsetto Lite to $499 for Truvaga Plus. Nurosym is excluded from this USD median because its current official listing is denominated in euros.
Figure 1. Observed prices in the NDL dataset. Price snapshots are date-sensitive and do not include tax, shipping or optional premium services. Source: Neuro Device Lab Consumer VNS Dataset, September 21, 2026.
| Device | Site | Observed price | Recurring-cost note |
|---|---|---|---|
| Pulsetto Lite | Cervical | $224 dataset snapshot | Core app usable without mandatory premium; gel required |
| Pulsetto FIT | Cervical | $269 dataset snapshot | Optional premium app; gel required |
| Pulsetto FIT X | Cervical | $399 dataset snapshot | New-generation Pulsetto platform; gel required |
| Truvaga 350 | Cervical | $325 | Finite 350-session device; conductive gel included initially |
| Truvaga Plus | Cervical | $499 | Rechargeable/unlimited-session positioning; electrode spray |
| Nurosym | Auricular | €700 / £599 regional official listing | No monthly fee; no gel required |
| Neuvana Xen | Auricular | $359 dataset snapshot | Recurring cost not fully verified |
| Vagustim V2 | Auricular | $349 dataset snapshot | Optional premium in some bundles |
| ZenoWell Vita Mini | Auricular | $239 | No mandatory app subscription identified |
| VeRelief Prime | Cervical | $399 dataset snapshot | Optional plan/consumable structure should be shown separately |
4. The evidence gap
NDL does not count a manufacturer bibliography as proof that a specific commercial device has been clinically validated. A study must be mapped to the exact device or technology platform, and manufacturer-posted research does not enter the peer-reviewed numerator until a journal publication is independently located.
Figure 2. Conservative platform-level evidence coverage in the current NDL audit. Source: Neuro Device Lab Consumer VNS Dataset, September 21, 2026.
| Platform | Peer-reviewed device/platform human evidence | Randomized | Credible sham | NDL treatment |
|---|---|---|---|---|
| Pulsetto | Verified | Yes | No equivalent stimulation sham located in the audited acute physiology study | Device/platform studied; clinical efficacy must not be inferred from study existence alone |
| Nurosym | Verified | Yes | Yes | Multiple device-specific human studies located |
| Neuvana Xen | Verified | Yes | Yes | Exact-device human study located |
| Vagustim | Verified | Yes | Yes | Includes a large sham-controlled trial whose primary endpoint was not met |
| Truvaga | Not yet verified in peer-reviewed exact-device literature | Not verified | Not verified | Manufacturer/consumer research kept separate; gammaCore evidence is not transferred to Truvaga |
| ZenoWell | Not yet independently mapped to exact current models | Not verified | Not verified | Manufacturer research claims remain evidence-gap items until mapped |
| VeRelief | Peer-reviewed publication not located in current audit | Manufacturer-posted study exists | Manufacturer-posted sham study exists | Visible, but excluded from peer-reviewed numerator |
Why negative evidence matters: Vagustim's ESTIVAL trial enrolled 142 participants in a multicentre, double-blind, sham-controlled design, but the primary pain endpoint was not met. NDL retains this study because evidence quality and evidence direction are different variables. A rigorous negative trial can be more informative than a small uncontrolled positive study.
5. Search demand: Pulsetto is growing with the category
Google Trends adds a different layer to the report: consumer attention. It does not report absolute search volume. Its index is normalized to time and geography, so the correct interpretation is relative interest and change, not raw query counts.
Figure 3A. English reconstruction of the supplied Google Trends data for “pulsetto,” worldwide, past 12 months. Same reported values; interface recreated for publication consistency.
Figure 3B. English reconstruction of the supplied Google Trends data for “pulsetto,” worldwide, past 3 months. Geographic values are normalized relative interest, not absolute volume.
Figure 3. User-captured Google Trends view for “pulsetto,” worldwide, last three months, accessed September 21, 2026. The view shows +6% versus the prior three-month period and +70% versus the same period one year earlier. Regional values represent relative search interest, not absolute search volume.
| Signal | Observed Trends result | How NDL interprets it |
|---|---|---|
| “pulsetto” — trailing 12 months | +170% vs prior year in the supplied Trends capture | Strong year-over-year relative interest growth; not a claim of +170% absolute search volume |
| “pulsetto” — trailing 3 months | +70% vs same period one year earlier | Recent interest remains materially above the comparable 2025 period |
| “pulsetto fit” — trailing 12 months | +400% related-query growth in the supplied capture | Supports treating FIT/FIT X as a dedicated branded-demand cluster |
| English-speaking relative-interest markets | Canada, Australia and United States appear prominently | Supports an English-language international SEO strategy rather than a US-only content model |
The commercial opportunity is not only “Pulsetto review.” The search journey runs from category discovery to brand evaluation: vagus nerve → vagus nerve stimulation → vagus nerve stimulator → Pulsetto → review/comparison → model selection.
6. Pulsetto as a case study in the consumerization of VNS
Why Pulsetto receives deeper editorial coverage in this report
Pulsetto illustrates several forces reshaping consumer VNS at once: hands-free cervical stimulation, an app-led experience, multiple price tiers, rapid product iteration and rising branded search interest. In September 2026, Pulsetto launched FIT X as the next generation of its platform, while FIT and Lite remained lower-cost entry points.
This section is intentionally deeper than a simple product listing, but it does not change NDL's evidence rules. Manufacturer claims, NDL observations and peer-reviewed findings remain separately labeled.
Research → Pulsetto Review → Hands-On → vs Nurosym / vs Truvaga / vs Sensate → Lite vs FIT vs FIT X → affiliate CTA
| Model | Role in lineup | Observed price | Editorial intent |
|---|---|---|---|
| Lite | Entry-level Pulsetto | $224 dataset snapshot | Budget / first-time buyer |
| FIT | Comfort/battery upgrade | $269 dataset snapshot | Core branded BOFU page |
| FIT X | Current-generation / adaptive platform | $399 dataset snapshot | New-product and model-comparison demand |
Continue the research
Evaluating Pulsetto?
Move from market-level data to hands-on testing, pricing, complaints and direct device comparisons before choosing a model.
7. Regulation is not one score
FDA medical-device status, CE medical-device conformity, FCC compliance and RoHS are not interchangeable. NDL therefore does not create a combined “certified” score. Truvaga's own site describes its products as general wellness products not evaluated by the FDA, while gammaCore is treated separately as a regulated clinical benchmark. Nurosym is positioned by its manufacturer as a CE-certified medical device.
Methodological guardrail: Evidence from gammaCore is not transferred to Truvaga simply because both are associated with electroCore. Likewise, research on a general taVNS modality is not automatically counted as exact-device evidence for a current commercial ear stimulator.
8. Methodology
Scope & denominator
NDL maintains both model-level and manufacturer/platform-level counts. Every percentage states its denominator. Direct electrical VNS is separated from non-electrical and adjacent nervous-system devices.
Pricing
List price, observed price, currency and access date are stored separately. Promotions are snapshots. Financing is not treated as a subscription.
Evidence
Manufacturer evidence claims and independently verified peer-reviewed evidence are separate fields. Each study is audited for device specificity, randomization, sham/control quality, sample size, conflicts and outcome status.
Negative studies
Trials remain in the dataset when their primary endpoint is not met. This reduces cherry-picking and prevents “has research” from becoming an endorsement.
Ownership cost
Base Year 1 and three-year cost include the observed device price plus mandatory recurring subscription and consumable costs. Optional premium services are excluded from the base metric.
Search trends
Google Trends is treated as normalized relative-interest data, not absolute volume. Query type, geography, period and access date must accompany any published statistic.
Open data: Publish the accompanying NDL Consumer VNS Dataset 2026 as a downloadable XLSX/CSV beside this report. Publishers citing derived statistics should cite the report, dataset version and September 21, 2026 cutoff date.
9. Citation-ready findings
“In Neuro Device Lab’s September 2026 audit, the median observed price among USD-priced direct-electrical consumer VNS models was $354.”
“NDL independently verified peer-reviewed device- or platform-specific human evidence for 4 of 7 consumer VNS platforms in its conservative 2026 audit.”
“Only 3 of 7 audited consumer VNS platforms had credible sham-controlled device/platform evidence located under NDL’s conservative criteria.”
“Google Trends data supplied to NDL showed worldwide relative search interest for ‘Pulsetto’ running 70% above the same three-month period a year earlier as of September 21, 2026.”
10. Limitations
This is a living market audit, not a clinical guideline. Device availability, prices, promotions, app plans, product names and regulatory positioning can change. Search-interest values are normalized. Evidence counts depend on the report's inclusion rules and should not be interpreted as proof of efficacy, superiority or safety for an individual user. Medical decisions should be made with a qualified clinician.
References & primary sources
- Peer-reviewed review of over-the-counter VNS and consumer device landscape: PMC12960021.
- Pulsetto official product family and FIT X/FIT/Lite pricing/positioning: Pulsetto.
- Pulsetto FIT X launch announcement, September 17, 2026: PR Newswire.
- Nurosym official product listing: Nurosym.
- Truvaga official shop and product disclosures: Truvaga.
- ZenoWell official Luna and Vita listings: Luna; Vita Mini.
- Nurosym randomized/device-specific research audit source: PMC13230338.
- Nurosym mechanistic HD-DOT study: PMC12938713.
- Vagustim ESTIVAL randomized sham-controlled trial: PubMed 41380709.
- Neuvana Xen device-specific study: PMC11282064.
- Pulsetto device/platform physiological study: American Journal of Physiology.
- Safety meta-analysis of transcutaneous auricular VNS: PMC9772204.
- Systematic review discussing sham/blinding heterogeneity in auricular VNS: PMC8120162.
Suggested citation: Neuro Device Lab. Consumer Vagus Nerve Stimulation Market Report 2026: Devices, Pricing, Scientific Evidence, Technology & Search Demand. September 21, 2026.